Payment overview · 2025
General Payments
$179.34
10 reported records · 7 companies
Healthcare provider profile · identity verified
Claire Ault, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TWIN CITY, GA · NPI 1710428255
Verified facts
What the public records show
CMS Open Payments records show Claire Ault, NP received $179.34 in general payments during 2025 across 10 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $43.33 | 24.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.05 | 20.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.92 | 16.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.95 | 10.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.95 | 10.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16.14 | 9.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.00 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $159.12 | 9 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.92 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $16.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 332 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 71 |
| Lisinopril | Lisinopril | 244 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 53 |
| Losartan Potassium | Losartan Potassium | 210 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 41 |
| Gabapentin | Gabapentin | 154 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 29 |
| Ozempic | Semaglutide | 139 | 25 |
| Omeprazole | Omeprazole | 124 | 27 |
| Famotidine | Famotidine | 117 | 27 |
| Metformin Hcl | Metformin Hcl | 111 | 24 |
| Simvastatin | Simvastatin | 109 | 22 |
| Prednisone | Prednisone | 98 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 22 |
| Montelukast Sodium | Montelukast Sodium | 94 | 25 |
| Meloxicam | Meloxicam | 92 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 24 |
| Tramadol Hcl | Tramadol Hcl | 91 | 20 |
| Alendronate Sodium | Alendronate Sodium | 85 | 17 |
| Ezetimibe | Ezetimibe | 83 | 19 |
| Potassium Chloride | Potassium Chloride | 83 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 19 |
| Trazodone Hcl | Trazodone Hcl | 80 | 16 |
| Furosemide | Furosemide | 77 | 20 |
| Allopurinol | Allopurinol | 75 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 14 |
| Azithromycin | Azithromycin | 65 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 18 |
| Carvedilol | Carvedilol | 56 | 18 |
| Sertraline Hcl | Sertraline Hcl | 55 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 12 |
| Alprazolam | Alprazolam | 52 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | suppressed |
| Baclofen | Baclofen | 48 | 12 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Atenolol | Atenolol | 45 | suppressed |
| Linzess | Linaclotide | 44 | 17 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 17 |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Glipizide | Glipizide | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 20 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 13 |
| Colchicine | Colchicine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Desloratadine | Desloratadine | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $179.34 · 10 records | Takeda Pharmaceuticals U.S.A., Inc. | AUSTEDO XR, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, GLASSIA, JARDIANCE, Kerendia, REPATHA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error